Notice of Proposed Sale · 144

Revolution Medicines, Inc.

RVMDNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Aug 21, 2026Accepted Aug 21, 2026, 4:38 PM EDTFiling CIK 1246842Accession 0001950047-26-008545

View company →Permanent SEC source ↗

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer: REVOLUTION MEDICINES INC
Issuer CIK: 0001628171
SEC file number: 001-39219
Phone: 6504816801
Person for whose account securities are to be sold: THE JONATHAN GOLDSMITH REVOCABLE TRUST
Relationships to issuer: Director · Officer
Street: 700 Saginaw Drive
City: Redwood City
State / country code: CA
Postal code: 94063

Securities proposed for sale

Securities proposed for sale · 1 reported row
Security	Proposed units	Aggregate market value	Units outstanding	Approximate sale date	Exchange	Broker / market maker
Common	3,000	635,205.00	214,336,418	08/21/2026	NASDAQ	Morgan Stanley Smith Barney LLC Executive Financial Services

Broker / market maker — proposed row 1, entry 1

Name: Morgan Stanley Smith Barney LLC Executive Financial Services
Street: 1 New York Plaza
Street (continued): 8th Floor
City: New York
State / country code: NY
Postal code: 10004

Acquisition of securities to be sold

Acquisition of securities to be sold · 1 reported row
Security	Acquired	Nature of acquisition	Acquired from	Amount acquired	Gift transaction	Payment date	Nature of payment
Common	11/25/2014	Founders Shares	Issuer	3,000	N	11/25/2014	N/A

Sales reported in the preceding three months

Sales reported in the preceding three months · 1 reported row
Seller	Security	Sale date	Amount sold	Gross proceeds
MARK A GOLDSMITH	Common	06/16/2026	10,020	1,564,310.38

Seller — prior-sale row 1, entry 1

Name: MARK A GOLDSMITH
Street: 700 Saginaw Drive
City: Redwood City
State / country code: CA
Postal code: 94063

Prior-sale reporting

Nothing to report for the preceding three months: N

Notice signature

Notice date: 08/21/2026
Signed: /s/ Mark A Goldsmith, Trustee
Plan adoption dates: 05/22/2026

Company context

Revolution Medicines is a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide. For more information, visit www.revmed.com and follow Revolution Medicines on LinkedIn, X (Twitter) and Instagram.

Current securities

RVMDNASDAQ · EQUITY · Current RVMDWNASDAQ · WARRANT · Current

Get the free weekly BCS email.